ABSTRACT
COVID-19, caused by the SARS-CoV-2 virus, is a highly pathogenic emerging infectious disease. Healthcare personnel (HCP) are presumably at higher risk of acquiring emerging infections because of occupational exposure. The prevalence of COVID-19 in HCP is unknown, particularly in low- to middle-income countries like El Salvador. The goal of this study was to determine the seroprevalence of anti-SARS-CoV-2 antibodies among HCP in El Salvador just prior to vaccine rollout in March 2021. We evaluated 2176 participants from a nationally representative sample of national healthcare institutions. We found 40.4% (n = 880) of the study participants were seropositive for anti-spike protein antibodies. Significant factors associated with infection included younger age; living within the central, more populated zone of the country; living in a larger household (≥7 members); household members with COVID-19 or compatible symptoms; and those who worked in auxiliary services (i.e., housekeeping and food services). These findings provide insight into opportunities to mitigate SARS-CoV-2 risk and other emerging respiratory pathogens in HCP in El Salvador.
ABSTRACT
Este documento tiene como objetivo presentar la evidencia disponible sobre las opciones terapeutas contra el Covid-19. Se presentan 2 Tablas, la primera resume la descripción de cada medicamento y la conclusión con respecto a su uso como tratamiento contra el SARS-Covid-2, de acuerdo con la evidencia disponible al momento y en la segunda tabla se muestra esta evidencia
This document aims to present the available evidence on the therapeutic options against Covid-19. Two tables are presented, the first one summarizes the description of each drug and the conclusion regarding its use as a treatment against SARS-Covid-2, according to the evidence available at the time and the second table shows this evidence
